765 related articles for article (PubMed ID: 31365094)
61. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.
Both A; Büttner H; Huang J; Perbandt M; Belmar Campos C; Christner M; Maurer FP; Kluge S; König C; Aepfelbacher M; Wichmann D; Rohde H
J Antimicrob Chemother; 2017 Sep; 72(9):2483-2488. PubMed ID: 28637339
[TBL] [Abstract][Full Text] [Related]
62. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
63. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
[TBL] [Abstract][Full Text] [Related]
64. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
65. Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.
Humphries RM; Hemarajata P
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396547
[No Abstract] [Full Text] [Related]
66. Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36).
Gaibani P; Ambretti S; Campoli C; Viale P; Re MC
Int J Antimicrob Agents; 2020 Jan; 55(1):105816. PubMed ID: 31593765
[No Abstract] [Full Text] [Related]
67. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P
Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262
[TBL] [Abstract][Full Text] [Related]
68. KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam.
Hobson CA; Bonacorsi S; Jacquier H; Choudhury A; Magnan M; Cointe A; Bercot B; Tenaillon O; Birgy A
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020157
[TBL] [Abstract][Full Text] [Related]
69. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.
Antonelli A; Giani T; Di Pilato V; Riccobono E; Perriello G; Mencacci A; Rossolini GM
J Antimicrob Chemother; 2019 Aug; 74(8):2464-2466. PubMed ID: 31318973
[No Abstract] [Full Text] [Related]
70. Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
Shen S; Tang C; Ding L; Han R; Yin D; Yang W; Guo Y; Hu F
mSphere; 2022 Dec; 7(6):e0048722. PubMed ID: 36374086
[TBL] [Abstract][Full Text] [Related]
71. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
72. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
[TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
74. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
[TBL] [Abstract][Full Text] [Related]
75. Changing Characteristics and
Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
[TBL] [Abstract][Full Text] [Related]
76. Spread and evolution of bla
Yang W; Tang C; Shen S; Shi Q; Hu F
Int J Antimicrob Agents; 2024 May; 63(5):107149. PubMed ID: 38508537
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
Wang F; Zhou Q; Yang X; Bai Y; Cui J
PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
[TBL] [Abstract][Full Text] [Related]
78. Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β-Lactamase.
Taracila MA; Bethel CR; Hujer AM; Papp-Wallace KM; Barnes MD; Rutter JD; VanPelt J; Shurina BA; van den Akker F; Clancy CJ; Nguyen MH; Cheng S; Shields RK; Page RC; Bonomo RA
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0212421. PubMed ID: 35311523
[TBL] [Abstract][Full Text] [Related]
79.
Findlay J; Rens C; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0091822. PubMed ID: 36154170
[TBL] [Abstract][Full Text] [Related]
80. Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background.
Sun L; Chen W; Li H; Li L; Zou X; Zhao J; Lu B; Li B; Wang C; Li H; Liu Y; Cao B
J Antimicrob Chemother; 2020 Oct; 75(10):3072-3074. PubMed ID: 32719857
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
